Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (1709)	12/3/1999 11:40:00 AM
From: Hank	Respond to of 5582

"...if an announcement is made that the studies will be published, the stock will gap over $20." I seriously doubt that. The stock never gapped that big when they announced the AJIC article. Let's just say that I am willing to take my chances. As for the "independent" researchers conducting the second study, I'd have to know who they are and what their relationship is to GUMM before I'd believe they were truly independent and unbiased. I think they will have to try hard to convince the editors of any reputable scientific journal of their independent status as well. However, IF they get the studies published, that does not necessarily mean that the data will be good enough to convince the scientific/medical community that Zicam really works as advertised. In other words, getting a paper published doesn't mean the conclusions being drawn from the data by the authors are entirely valid. I'd love to be more specific but until I actually SEE a paper on Zicam, it's all guess work, as usual.